• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Schmid John P.

    6/12/25 4:30:16 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DSGN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Schmid John P.

    (Last) (First) (Middle)
    C/O DESIGN THERAPEUTICS, INC.
    6005 HIDDEN VALLEY ROAD, SUITE 110

    (Street)
    CARLSBAD CA 92011

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Design Therapeutics, Inc. [ DSGN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/10/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $4.01 06/10/2025 A 19,000 (1) 06/09/2035 Common Stock 19,000 $0 19,000 D
    Explanation of Responses:
    1. The shares subject to the option vest in equal monthly installments over 12 months following June 10, 2025 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.
    /s/ Mustapha Parekh, Attorney-in-Fact 06/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DSGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DSGN

    DatePrice TargetRatingAnalyst
    5/7/2024$6.00 → $12.00Neutral → Overweight
    Piper Sandler
    11/14/2023$42.00 → $6.00Overweight → Neutral
    Piper Sandler
    8/15/2023$19.00 → $6.00Outperform → Neutral
    Wedbush
    8/15/2023$23.00 → $7.00Outperform → Sector Perform
    RBC Capital Mkts
    8/15/2023$6.00Outperform → Market Perform
    SVB Securities
    5/4/2023$6.00Sell → Neutral
    Goldman
    6/10/2022$21.00Outperform
    Wedbush
    5/2/2022$30.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $DSGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

      Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND Application to Open U.S. Sites CARLSBAD, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the first Friedreich ataxia (FA) patient has been dosed via intravenous (IV) infusion in its RESTORE-FA (Reactivating Expression Suppressed Through Overcoming Repeat Expansion for FA) open-label

      6/4/25 7:00:00 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

      CARLSBAD, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present during the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 p.m. ET in New York. A live webcast of the presentation will be available here and in the investors section of the company's website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on

      5/28/25 8:00:00 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

      CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company's website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new cla

      5/13/25 8:00:00 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    SEC Filings

    See more
    • Design Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Design Therapeutics, Inc. (0001807120) (Filer)

      6/12/25 4:18:23 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Design Therapeutics Inc.

      EFFECT - Design Therapeutics, Inc. (0001807120) (Filer)

      5/19/25 12:15:15 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Design Therapeutics Inc.

      S-3 - Design Therapeutics, Inc. (0001807120) (Filer)

      5/7/25 4:54:16 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Schmid John P. bought $99,738 worth of shares (26,965 units at $3.70) (SEC Form 4)

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      3/25/24 7:10:26 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berger Heather A. bought $4,866 worth of shares (1,300 units at $3.74) (SEC Form 4)

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      3/25/24 7:09:14 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lappe Rodney W bought $49,287 worth of shares (21,000 units at $2.35), increasing direct ownership by 19% to 133,024 units (SEC Form 4)

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      10/2/23 6:01:58 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director George Simeon

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      6/12/25 4:48:21 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director William Arsani

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      6/12/25 4:30:20 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Prasad Deepa

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      6/12/25 4:30:24 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Design Therapeutics upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Design Therapeutics from Neutral to Overweight and set a new price target of $12.00 from $6.00 previously

      5/7/24 6:22:26 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Design Therapeutics from Overweight to Neutral and set a new price target of $6.00 from $42.00 previously

      11/14/23 11:39:53 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics downgraded by Wedbush with a new price target

      Wedbush downgraded Design Therapeutics from Outperform to Neutral and set a new price target of $6.00 from $19.00 previously

      8/15/23 7:30:45 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care